Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis advised Turn/River Capital, while White & Case and Meitar Law Office advised Tufin Software Technologies Ltd. on the deal. Latham & Watkins advised...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented ParaFi Capital in the transaction. OXIO, the first telecom-as-a-service platform for brands and enterprises with a white-label, fully-customizable solution to help turn...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented SLR Investment Corp. in the transaction. Vapotherm, Inc., a global medical technology company focused on the development and commercialization of non-invasive technologies...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented ParaFi Capital in the transaction. ConsenSys closed a US$450 million financing round, bringing its valuation to over US$7 billion. ParaFi Capital led this...
You must be a Standard 1 Year member to access this content.
Davis Polk and Gross & Co. advised SatixFy Communications Ltd. on the deal. Appleby and Morrison & Foerster acted for Endurance Acquisition Corp. Latham & Watkins...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
You must be a Standard 1 Year member to access this content.
Latham & Watkins, Paul, Weiss, Herzog Fox & Neeman, Shartsis Friese, and Poultan & Yordan acted on the deal. Chess.com, the world’s largest chess platform, has...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Silver Spike Acquisition Corp. II on the deal, while Latham & Watkins represented Eleusis. Silver Spike Acquisition Corp. II announced its approximately $446...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Mesoblast in the transaction. Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has...
You must be a Standard 1 Year member to access this content.
